American Society of Hematology


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to American Society of Hematology: American Society of Clinical Oncology, PubMed

American Society of Hematology

,

ASH

An organization of professional hematologists that provides care to patients with diseases of the blood and promotes education, research, and training within the field. ASH also serves as an advocacy group for the profession.
References in periodicals archive ?
Abstract presented at the American Society of Hematology Annual Meeting, Orlando, FL.
Monica Mosquera-Caro said at the annual meeting of the American Society of Hematology.
Cerus and Baxter are submitting the results of the European Phase 3 clinical trial for presentation at the annual meeting of the American Society of Hematology in December 2000.
The marketing authorization for ADCETRIS is based on positive results from the ECHELON-1 phase 3 clinical trial that were presented in the Plenary Scientific Session at the 59th American Society of Hematology annual meeting in December 2017 with simultaneous publication in the New England Journal of Medicine.
The American Society of Hematology is a professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood.
Early data from the relapsed or refractory acute myeloid leukaemia patients in this study were presented at the 2015 American Society of Hematology Annual Meeting.
The data were presented last Saturday, at the annual conference of the American Society of Hematology.
American Society of Hematology guidelines on immunologic thrombocytopenia, last updated in 1996, state that thyroid function evaluation has "uncertain appropriateness" in adults with immunologic thrombocytopenia.
However, doses of 40 and 60 mg/day of the new drug caused excess bleeding episodes, Turpie reported last week at a meeting in Atlanta of the American Society of Hematology.
Sunderji reported at the annual meeting of the American Society of Hematology.
Results from the CA180-372 trial presented at the 2017 American Society of Hematology Annual Meeting showed that at three years, the combination of Sprycel and chemotherapy demonstrated an event-free survival rate, the study's primary endpoint, of 65.5%, and an overall survival rate of 91.5%.

Full browser ?